Intracellular PD Modelling (<i>PD</i><sub>i</sub>) for the Prediction of Clinical Activity of Increased Rifampicin Dosing.

It is important to underline, however, that there may be significant additional patient benefits derived from >35 mg/kg RIF doses that are not captured here using the PD i -based PK–PD modelling e.g., relapse rates.

also in 13,097 other papers